BioTelemetry (BEAT) PT Raised to $74 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BEAT Hot Sheet
Price: $0.42 --0%
Rating Summary:
7 Buy, 8 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 2
Rating Summary:
7 Buy, 8 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 2
Join SI Premium – FREE
Raymond James analyst Jayson Bedford raised the price target on BioTelemetry (NASDAQ: BEAT) to $74.00 (from $64.00) while maintaining a Outperform rating.
Bedford said the Geneva deal offers a new source of growth/upside.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dianthus Therapeutics (DNTH) PT Raised to $134 at Raymond James
- Bristow Group (VTOL) PT Lowered to $63 at Raymond James
- CAVA Group Inc (CAVA) PT Lowered to $76 at Telsey
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Raymond JamesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
